
	Where results make sense

Topic: Gentris

Related Topics

Landed gentry

History of England

Wickford

English Civil War

Gentry County, Missouri

History of British society

Qing Dynasty

Szlachta

1361

History of Russia

Hispania Baetica

Second Estate

Justice of the peace

Rotten borough

Three Principles of the People

In the News (Fri 27 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	newsobserver.com
		Gentris, which makes gene-based tests used by companies doing clinical trials on new drugs, is teaming with Falco Biosystems, one of the largest medical testing laboratories in Japan.
		Gentris hopes to make a similar deal to establish a European testing facility in about a year, said Lee Richardson, Gentris' director of international corporate development.
		Gentris' work is in the field of pharmacogenomics, a personalized, gene-based approach to drug research, development and therapy that is considered to be the future of medicine.
	www.newsobserver.com /104/v-print/story/480763.html (415 words)

	Hobart and William Smith Colleges :: News Releases
		Prior to joining Gentris as a founder, and board member, Gessner served for over 20 years in business development and clinical services management positions.
		Gentris Corporation is developing products to predict drug efficacy and to dramatically decrease adverse drug reactions, which is the fourth leading cause of death and the fifth leading cause of illness in the United States.
		The ultimate benefit to these organizations is to shorten drug development cycles, improve new drug approval rates, and allow drugs that might have otherwise been abandoned advance towards final approval and be prescribed to a targeted subset of the population.
	www.hws.edu /news/update/showwebclip.asp?webclipid=623 (863 words)

	Portfolio Companies - Gentris
		Gentris Corporation is a pharmacogenomics company engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomics products.
		Gentris believes that the application of pharmacogenomics knowledge to drug development will improve trial design and predictability, shortening the drug development cycle, improving new drug approval rates and market positioning, and enabling companies to retest drug candidates that fail to meet clinical trial or FDA approval standards.
		Gentris is using the knowledge and expertise gained through the laboratory testing component to develop and commercialize Clinical Pharmacogenomic Diagnostic Kits.
	www.rtventures.com /companies/gentris.htm (162 words)

	Gentris • Revolutionizing Medicine Through Pharmacogenomics ®
		Gentris Corporation is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions.
		As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market more quickly.
		Gentris is developing diagnostic test kits and validated reference controls that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics.
	www.gentris.com (158 words)

	Gentris, Unarmed Combat (Private) - Alleria
		As the right was being bent Gentris akwardly maintained a 90 degree angle and the tip of his right foot wich was pointing forward.
		Gentris responded immediately, as soon as he recieved instructions from his teacher he obeyed.
		Gentris felt uncomfortable at first about how much older he was than his teacher.
	www.alleria.com /forums/showthread.php?t=7154 (1896 words)

	Pharma Focus Asia - Pharma News
		Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, announced that the company has partnered with FALCO biosystems Ltd. (FALCO), one of the largest publicly traded medical testing laboratories in Japan.
		Gentris currently serves a large client base of pharmaceutical companies in Japan and hence has developed a strong reputation and brand within the market.
		Michael Murphy, CEO, Gentris said, "It is evident that pharmacogenomics is going to be as important to drug development, and ultimately the public, in Japan as it is in the United States and Europe.
	www.pharmafocusasia.com /pharma_news/?NewsID=91 (225 words)

	BioSpace - Gentris Corporation News, Search Jobs, Events
		Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).
		Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle.
		Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products.
	www.biospace.com /company_profile.aspx?CompanyId=346804 (589 words)

	Gentris Partners with FALCO biosystems
		The partnership, to be called “Gentris Japan”, will offer pharmacogenomics services to the pharmaceutical industry in Japan, the second-largest pharmaceutical market in the world after the United States.
		The partnership is a natural, strategic move for both Gentris and FALCO as global pharmaceutical companies in Japan increasingly look to effectively integrate pharmacogenomics into their drug development programs.
		Gentris already serves a large client base of pharmaceutical companies in Japan and therefore has developed a strong reputation and brand within the market.
	www.prleap.com /pr/45448 (541 words)

	Big Step For Gentris: Genomics Firm Submits Tests For FDA Approval :: WRAL.com
		Gentris has submitted information based on clinical tests seeking Food and Drug Administration approval for a series of genetics-based tests.
		Gentris’ submission is for tests centered on the so-called CYP2D6 gene, which is a liver enzyme that metabolizes some 20 percent of all commonly prescribed drugs, according to Gentris.
		Gentris’ submission to the FDA is based on trials at three different sites.
	www.wral.com /news/local/story/1088132 (424 words)

	[No title]
		Gentris and Nanogen will initially target clinical research customers for assays resulting from the Agreement, which we will seek to develop as turnkey, 'off the shelf' solutions.
		Gentris Corporation is engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomic products and services.
		Nanogen's goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics.
	www.snl.com /interactive/ir/4097115/news/020502.htm (680 words)

	Medcompare - Diagnostics News : Gentris Corporation Announces FDA 510(k) Submission For GentriSure Human Genomic DNA ...
		Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced that the company has completed an FDA 510(k) submission for six Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene (CYP2D6).
		Gentris’ reference controls are the first commercially available source of well-characterized and consistent genomic material for CYP2D6 testing, obtained with informed consent, and produced under Good Manufacturing Practice (GMP) conditions.
		Gentris has already identified distributors for GentriSure Human Genomic DNA Reference Controls in the U.S and Europe, and is currently seeking distribution partners in Japan.
	www.medcompare.com /news.asp?newsid=157161 (624 words)

	Gentris corporation
		Subscribe to our "Careers in the Biopharmaceutical Industry" newsletter:
		Gentris Corporation (website) is a pharmacogenomics company based in Research Triangle Park in North Carolina.
		Founded by Michael Murphy in 2001, Gentris has gained prominence in the pharmacogenomics industry thanks to favorable media attention and revolutionary methods.
	www.ibpassociation.org /encyclopedia/Pharmacy/Gentris_corporation.php (71 words)

	Company Overview Recent Developments (Site not responding. Last check: 2007-10-27)
		Research Triangle Park, N.C., November 27, 2001 —Gentris Corporation, a clinical pharmacogenomics testing and diagnostic products company, has signed a collaboration agreement with MDS Pharma Services, a contract research organization, based in Montreal, Quebec, to establish a confidential database of genotyped volunteers and a repository for commercial development of diagnostic reference controls.
		The collaboration with MDS provides Gentris access to samples that will be immediately commercialized by the company and with collaborators, as validated reference controls to support pharmacogenomic diagnostics.
		Gentris Corporation is a pharmacogenomics company engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomics products.
	www.mdsps.com /over/2001/o_press32.htm (365 words)

	triangletechjournal (Site not responding. Last check: 2007-10-27)
		-- Gentris Corporation announced today that it had secured $1.5 million in funding from a combination of institutional and angel investors, including Research Triangle Ventures, which is headed up by prominent tech attorney Fred Hutchison.
		The Gentris management team are pioneers in the pharmacogenomic space, and are led by CEO Michael Murphy.
		Gentris Corporation is engaged in the development and rapid
	www.triangletechjournal.homestead.com /mar2002gentris.html (546 words)

	Gentris Signs Partnership With Japanese Medical Testing Firm For Personalized Medicine - WRAL.com
		Gentris is partnering with FALCO Biosystems of Japan to form "Gentris Japan," the goal being to help develop personalized medicine based on genomics.
		To lead the effort, Gentris hired Lee Richardson, who had been a consultant with the firm.
		The Japanese firm also utilizes a falcon as its logo, relating FALCO to the Latin word meaning falcon and the fact that the falcons are "partners" in hunting with man.
	www.wral.com /news/local/story/1057673/?print_friendly=1 (528 words)

	Clinical Lab Products
		Gentris Corp has signed a sub-licensing agreement with Mayo Foundation for Medical Education and Research to provide genetic testing services for the UGT1A1 gene.
		The UGT1A1 gene is known to be involved in the metabolism of irinotecan (Camptosar®), a commonly prescribed first-line treatment for advanced colon cancer and rectal cancer.
		As a result of this non-exclusive agreement with Mayo Foundation for Medical Education and Research, Gentris is poised to offer UGT1A1 genotyping for cancer patients being treated with irinotecan.
	www.clpmag.com /news.php?p=4 (231 words)

	Gentris Promotes Karen Nield to VP, Finance and Human Resources
		Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced the promotion of Karen Nield to VP, Finance and Human Resources.
		She will lead Gentris in standardizing human resources policies, attracting top talent and strengthening employee benefits.
		Nield is a CPA with more than 13 years of broad range public and private industry accounting experience with specialties in financial forecasting and maintaining compliance of state laws and reporting standards.
	www.prweb.com /releases/2006/9/prweb437796.htm (541 words)

	Council For Entrepreneurial Development: Regional News, May 2, 2005
		Through its innovative application of pharmacogenomics, Gentris helps pharmaceutical companies determine which patients are likely to respond to certain drugs according to their unique genetic makeup.
		The funding will allow Gentris to proceed with its plan to develop and distribute pharmacogenomic diagnostic testing kits to help hospitals and doctors determine how a patient will respond to a drug.
		Gentris’ recent funding comes one month after the U.S. Food and Drug Administration issued guidance on pharmacogenomic data submissions.
	www.cednc.org /news/regional_news/2005/05022005.html (1051 words)

	CEDNC: News: EntreNews: March 25, 2002
		Morrisville-based Gentris Corporation raised $1.5 million in its initial round of funding to accelerate its product development and marketing efforts, according to the News and Observer.
		Gentris advances and applies the science of pharmacogenomics (the study of patients' response to drug treatment based on individual genetic variations) to clinical drug development and point-of-care diagnostics.
		Gentris is generating its initial revenue by performing tests to help pharmaceutical companies and contract research organizations conduct more cost-effective clinical trials.
	www.cednc.org /news/regional_news/2002/3_25.html (789 words)

	Medical Device Link
		Research Triangle Park, North Carolina - December 15, 2005 - Gentris Corporation, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, announced today that Scott Clark, Ph.D., has been promoted to Vice President of Research and Development from the position of Executive Director of Scientific Affairs.
		Gentris has also recruited accomplished scientist Heath Knight, Ph.D., as Vice President of Business Development.
		A seasoned expert with over fifteen years experience in pharmacogenomics, Clark will be responsible for Gentris' scientific strategy and will manage the Clinical Genetics Research and Development Division.
	www.devicelink.com /newcc/announcement.php?newsID=6 (344 words)

	i-Newswire.com - Press Release And News Distribution - Gentris Corporation Expands GentriSure Line of Human Genomic DNA ... (Site not responding. Last check: 2007-10-27)
		Genetic tests are available to identify patients at risk for experiencing adverse reactions to the drug, however, until the introduction of the GentriSure line of Human Genomic DNA Reference Controls, no consistent source of properly consented material had been available.
		In April 2006 Gentris introduced Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 (CYP2D6) gene.
		We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
	i-newswire.com /pr80096.html (614 words)

	TechJournal South - Article
		Gentris has been developing products and services in the emerging field of applied clinical pharmacogenomics and diagnostic solutions.
		Through its application of pharmacogenomics, Gentris helps pharmaceutical companies determine which patients are likely to respond to certain drugs according to their unique genetic makeup.
		"Gentris already performs drug metabolism and safety tests like the ones the FDA is recommending," said Michael Murphy, CEO of Gentris.
	www.techjournalsouth.com /news/article.html?item_id=928 (335 words)

	CHI's Molecular Med Monthly Articles (Site not responding. Last check: 2007-10-27)
		Robust and accurate tests for genotyping will be important to advancing the field of pharmacogenomics—or "getting the right drugs to the right patients." Gentris provides genotyping services and is also developing diagnostic kits and reference standards for pharmacogenomic tests.
		Gentris president and CEO Michael P. Murphy discusses the company’s plans, as well as developing trends in pharmacogenomics.
		Getting FDA approval for products like ours is do-able, but it requires working with the FDA as a partner and bringing them in early on, which is what we have done.
	www.healthtech.com /newsarticles/issue18_2.asp (2249 words)

	Pharmalicensing.com: : Gentris and Sankyo Pharma establish partnership
		The partnership is a creative and far reaching agreement that will further both companies' aim to make the administration of drugs to patients significantly safer and more effective.
		While the partnership agreement is non-exclusive, it marks a major commitment by both companies to push forward the practical application of pharmacogenomics.
		"Gentris combines a high level of scientific expertise with an understanding of the regulatory requirements for executing pharmacogenomic studies," noted Dr. John Alexander, President of Sankyo Pharma Development.
	pharmalicensing.com /news/headlines/1046129600_3e5aabc0e07d8 (365 words)

	LGC and Gentris announce licensing agreement: News from LGC
		LGC is the exclusive licensor of this gene variation on behalf of Dundee University and cancer research UK.
		'Gentris is dedicated to helping our clients integrate pharmacogenomic testing into their drug development programmes to deliver safer, more effective compounds to the market sooner,' commented Gentris CEO Michael Murphy.
		This announcement coincides with the recent release of Gentris' proprietary human genomic DNA reference controls for the CYP2D6 gene, which are currently available for research use.
	www.laboratorytalk.com /news/uka/uka178.html (668 words)

	Gentris Corporation Announces Live Webcast : ArriveNet Press Releases : Technology (Site not responding. Last check: 2007-10-27)
		EDT to discuss trends and innovations in clinical and diagnostic pharmacogenomics and their impact on the pharmaceutical development community.
		Michael Murphy is the President and CEO of Gentris Corporation.
		Michael is considered an industry pioneer and thought leader with more than 22 years of scientific and business experience in the field of pharmacogenomics.
	press.arrivenet.com /technology/article.php/693543.html (579 words)

Try your search on: Qwika (all wikis)